NCT05650112View on ClinicalTrials.gov

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
HealthyEnteric Hyperoxaluria
Interventions
BIOLOGICAL

FB-001

FB-001 is formulated as a powder in capsule intended for oral administration

BIOLOGICAL

Placebo

In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule

Trial Locations (1)

45227

RECRUITING

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
lead

Federation Bio Inc.

INDUSTRY